Montreal Heart Institute
- Address
- 5000 Belanger Street
Sponsor Overview
Specializations
Cardiovascular disease prevention in type 2 diabetes
The Montreal Heart Institute is involved in research focused on reducing cardiovascular events in adults with type 2 diabetes who have not yet experienced prior cardiovascular disease. Its clinical activity in this area centers on prevention of major complications such as myocardial infarction, stroke, and cardiac arrest.
- Type 2 diabetes
- Cardiovascular risk reduction
- Primary prevention
The institute’s research interest extends to strategies aimed at limiting urgent coronary revascularization and other serious ischaemic complications in high-risk metabolic populations.
Anti-inflammatory and antiplatelet strategies
Its trial portfolio includes interest in colchicine and aspirin as therapies being evaluated for cardiovascular protection. This reflects a focus on medical approaches that target inflammation and platelet activity in patients with elevated atherothrombotic risk.
- Colchicine
- Aspirin
- Atherothrombosis
Research in this domain is directed toward improving outcomes in people with diabetes through therapies added to standard cardiovascular care.
Metabolic and cardiometabolic health
The sponsor’s clinical research activity addresses the overlap between metabolic disease and heart disease, with emphasis on patients living with diabetes but without established coronary artery disease. This places the institute within the broader field of cardiometabolic risk management.
- Diabetes-related vascular risk
- Coronary artery disease prevention
- Vascular complications
Its research interests are centered on preventing first-time cardiovascular complications in a population with significant long-term risk.
Multinational cardiovascular research collaboration
The Montreal Heart Institute participates in a broad collaborative research network spanning multiple sites and countries, supporting studies in cardiovascular medicine and diabetes care. This environment enables investigation of therapies intended for diverse patient populations across North America and beyond.
- International research sites
- Collaborative clinical research
- Cardiometabolic trials
Its clinical research landscape is shaped by work in high-risk preventive cardiology and treatment strategies for patients with diabetes and no prior cardiovascular events.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Colchicine and Carbaspirin Calcium in Cardiovascular Outcomes for Type 2 Diabetes Patients Without Prior Cardiovascular Events |  Denmark Finland France Greece Italy Portugal | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 46 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
46 centres- Address
- 41, Chemin de la Terrasse, 31500 Toulouse
- Address
- 9 passage Susan Sontag, 72 rue Césaria Evora, 75019 Paris
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Viale Luigi Pinto 1, 71122 Foggia
- Address
- Via Bartolomeo Fazio 30, 19121 La Spezia
- Address
- Corso Svizzera 164, 10149 Turin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Montreal Heart Institute.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.